top of page

Search Results

Results found for "Keltic Pharma Therapeutics"

  • Dr. Roger Sunahara | Dr. GPCR Ecosystem

    bases for ligand binding and efficacy to help optimize the design and engineering of more efficacious therapeutics perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic

  • Dr. Nicolas Gilles | Dr. GPCR Ecosystem

    He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

  • Dr. Christel Menet | Dr. GPCR Ecosystem

    I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.

  • Dr. Khaled Abdelrahman, Victoria Rasmussen and Madelyn Moore | Dr. GPCR Ecosystem

    He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)

  • Leadership, Impact, and GPCR Signaling with Dr. Michelle Halls | Dr. GPCR Ecosystem

    Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights concentrations, her work highlights why receptor localization and protein complex assembly matter for therapeutic localized signaling events, how these mechanisms are hijacked in disease, and how they can be leveraged for therapeutic

  • Annette Gilchrist: Native Cell Systems, Biased Agonism, and the Pharmacogenomics Gap | Dr. GPCR Ecosystem

    Whether a 20% reduction in beta-arrestin coupling matters therapeutically depends on the cell type, the drug response differences, and a largely unexplored opportunity in existing drug pipelines Antibody therapeutics Antibody therapeutics for GPCRs: the pipeline argument Biologics have a substantially higher success The combination of those two facts, Gilchrist argues, makes antibody-based GPCR therapeutics an underexplored The precedent of drugging a receptor without knowing what activates it naturally, and getting therapeutic

  • From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Ecosystem

    Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics

  • GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin | Dr. GPCR Ecosystem

    From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general

  • Dr. Juan JosĂ© Fung | Dr. GPCR Ecosystem

    Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Unlock the Full Dr.

  • Terry HĂ©bert | Dr. GPCR Ecosystem

    Hebert's argument — that challenge trials depend on a reliable therapeutic the field did not yet have Challenge trials and the therapeutic floor — Why the ethics of accelerating vaccine trials depend on challenge trial — where volunteers receive placebo or active virus — is ethically unworkable without a therapeutic Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

  • Dr. AurĂ©lien Rizk | Dr. GPCR Ecosystem

    the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

  • Paul Insel: Rethinking COVID-19 Pathobiology Through GPCR Signaling | Dr. GPCR Ecosystem

    The therapeutic logic that follows is less about attacking the virus and more about rebalancing a GPCR-driven Dry-lab pharmacology and what becomes possible when wet-lab work stops GPCR density and tissue-specific therapeutic The review was accepted at Clinical Pharmacology and Therapeutics within weeks. If the virus disrupts one arm of this receptor-peptide system, the therapeutic question stops being "

  • Dr. Khaled Abdelrahman | Dr. GPCR Ecosystem

    He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

  • Bryan Roth: Inside the DARPA Bet on a Non-Psychedelic Psychedelic | Dr. GPCR Ecosystem

    The therapeutic mechanism, however, is inseparable from the psychedelic experience itself, and not every questions in current GPCR pharmacology: can biased signaling at the serotonin 2A receptor decouple the therapeutic What you usually can't do is know which pathway, in which disease, will actually be therapeutic. The premise: psilocybin's therapeutic effect on depression is now well documented, but it is locked to

  • Dr. Rosie Dawaliby | Dr. GPCR Ecosystem

    In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

  • Dr. Stephane Angers | Dr. GPCR Ecosystem

    He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

  • Dr. Katarina Nemec | Dr. GPCR Ecosystem

    I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically

  • Tore Bengtsson: Rethinking β₂-Adrenergic Signaling in Metabolic Disease | Dr. GPCR Ecosystem

    Listeners gain insight into how basic GPCR pharmacology can translate into therapeutic strategies targeting He is also an entrepreneur and founder of biotechnology companies translating GPCR pharmacology into therapeutic GPCR signaling complexity and pathway selectivity Translating receptor pharmacology into metabolic therapeutics One is Sigrid Therapeutics, which focuses on digestion and metabolic regulation. That makes them unsuitable as long-term therapeutic drugs.

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Signals, pH, and Discovery : Cracking GPCR Mysteries with Dr. Ian Chronis | Dr. GPCR Ecosystem

    Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic micro environments could unlock new therapeutic strategies

  • Elva Zhao: G Protein Regulation and Biased Signaling at the GLP-1 Receptor | Dr. GPCR Ecosystem

    the most clinically validated targets in metabolic disease - yet the signaling logic separating the therapeutic pharmacologists have not yet addressed actually shape signaling output at one of the field's most important therapeutic receptor Transducer coupling as the missing mechanistic layer in GLP-1 receptor pharmacology The expanding therapeutic modulate the functional output at this receptor, and whether that regulatory layer contributes to the therapeutic

  • Dr. Lauren M. Slosky | Dr. GPCR Ecosystem

    protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

  • How Lipid Rafts Organize GPCR Signaling | Dr. GPCR Ecosystem

    Keyvan Sedaghat discussing how GPCR function is shaped by lipid raft compartmentalization, the expanding therapeutic efficacy and diagnostic innovation What the functional diversity of bitter taste receptors means for novel therapeutic

  • Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem

    His work carries direct translational relevance to diabetes and obesity therapeutics. opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic

  • Dr. Michael Feigin | Dr. GPCR Ecosystem

    Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic

  • Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem

    protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

  • Exploring Career Paths in GPCR Research with Dr. Jacek MokrosiĹ„ski | Dr. GPCR Ecosystem

    Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations

  • Yao Lu (Jackie) | Dr. GPCR Ecosystem

    molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

bottom of page